Skip to content
value.today

Genomind, Inc.

Total raised
$56 M
4 rounds on record
Latest round
$6 M
Nov 2020
First round on record
Apr 2014
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Genomind, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2020$6 MNo. 4$2 to $10 million

Genomind, Inc.: Raise no. 4, Nov 2020

Investors in this round

8 investors had bought by the notice of Apr 23, 2021: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $21 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Series D Preferred Stock and Common Stock Purchase Warrants
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Shawn Patrick O'Brien · Executive Officer, Director · Mr. O'Brien is the Chief Executive Officer and the Chairman of the Board of the Issuer.
  • Stephen Patrick Haller · Executive Officer · Mr. Haller is the Treasurer of the Issuer.
  • Tom Patrick Hess · Executive Officer · Mr. Hess is the Chief Financial Officer and Secretary of the Issuer.
  • Beth Patrick Dozoretz · Director
  • John Patrick Chadwick · Director
  • Shelloy Patrick Kiger · Director
  • Theresa Patrick Sexton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shawn Patrick O'Brien, Chief Executive Officer of the Issuer. Source: SEC Form D and 1 amendment, newest notice filed Apr 23, 2021. Read the notice at the SEC.

equity, optionsSEC
Jul 2018$21 MNo. 3$10 to $50 million

Genomind, Inc.: Raise no. 3, Jul 2018

Investors in this round

2 investors had bought by the notice of Sep 17, 2020: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $22 M offered; $1 M still to sell
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gloria P. Nuss · Executive Officer
  • Kip P. Olmstead · Executive Officer
  • Shawn P. O'Brien · Executive Officer, Director
  • Stephen P. Haller · Executive Officer
  • Thomas P. Hess · Executive Officer
  • Brad P. Lucas · Director
  • John P. Chadwick · Director
  • Joseph P. Anton · Director
  • Theresa P. Sexton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Hess, Chief Financial Officer. Source: SEC Form D and 3 amendments, newest notice filed Sep 17, 2020. Read the notice at the SEC.

equitySEC
Feb 2017$8 MNo. 2$2 to $10 million

Genomind, Inc.: Raise no. 2, Feb 2017

Investors in this round

5 investors had bought by the notice of Oct 24, 2017: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $14 M offered; $6 M still to sell
Smallest investment taken
$250,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Beth E. Dozoretz · Executive Officer, Director
  • Gloria E. Nuss · Executive Officer
  • Michael I. Koffler · Executive Officer, Director, Promoter
  • Ronald I. Dozoretz · Executive Officer, Director, Promoter
  • Stephen E. Haller · Executive Officer
  • Thomas E. Hess · Executive Officer
  • John E. Chadwick · Director
  • Joseph E. Anton · Director
  • Rina E. Wolf · Director
  • Theresa E. Sexton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Koffler, President. Source: SEC Form D and 1 amendment, newest notice filed Oct 24, 2017. Read the notice at the SEC.

equitySEC
Apr 2014$21 MNo. 1$10 to $50 million

Genomind, Inc.: Raise no. 1, Apr 2014

Investors in this round

6 investors had bought by the notice of Jul 15, 2016: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $26 M offered; $5 M still to sell
Smallest investment taken
$200,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Beth E. Dozoretz · Executive Officer, Director
  • Gloria E. Nuss · Executive Officer
  • Michael I. Koffler · Executive Officer, Director, Promoter
  • Ronald I. Dozoretz · Executive Officer, Director, Promoter
  • Stephen E. Haller · Executive Officer
  • Thomas E. Hess · Executive Officer
  • John E. Chadwick · Director
  • Joseph E. Anton · Director
  • Rina E. Wolf · Director
  • Theresa E. Sexton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Koffler, President. Source: SEC Form D and 7 amendments, newest notice filed Jul 15, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Genomind, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2021).

    SEC Form D · Apr 2021

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Apr 2021

That is all the official record says: Genomind, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Genomind, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Genomind, Inc.
NameRoleNamed in
Shawn Patrick O'BrienMr. O'Brien is the Chief Executive Officer and the Chairman of the Board of the Issuer.Apr 2021
Stephen Patrick HallerMr. Haller is the Treasurer of the Issuer.Apr 2021
Tom Patrick HessMr. Hess is the Chief Financial Officer and Secretary of the Issuer.Apr 2021
Gloria P. NussExecutive officerSep 2020
Kip P. OlmsteadExecutive officerSep 2020
Shawn P. O'BrienExecutive officerSep 2020
Stephen P. HallerExecutive officerSep 2020
Thomas P. HessExecutive officerSep 2020
Beth E. DozoretzExecutive officerDec 2018
Gloria E. NussExecutive officerDec 2018
Kip E. OlmsteadExecutive officerDec 2018
Ronald I. DozoretzExecutive officerDec 2018
Stephen E. HallerExecutive officerDec 2018
Thomas E. HessExecutive officerDec 2018
Michael I. KofflerExecutive officerOct 2017
Scott I. StorrerExecutive officerApr 2014
Stacy E. WilliamsExecutive officerApr 2014
Beth Patrick DozoretzDirectorApr 2021
John Patrick ChadwickDirectorApr 2021
Shawn Patrick O'BrienMr. O'Brien is the Chief Executive Officer and the Chairman of the Board of the Issuer.Apr 2021
Shelloy Patrick KigerDirectorApr 2021
Theresa Patrick SextonDirectorApr 2021
Brad Patrick LucasDirectorDec 2020
Joseph Patrick AntonDirectorDec 2020
Brad P. LucasDirectorSep 2020
John P. ChadwickDirectorSep 2020
Joseph P. AntonDirectorSep 2020
Shawn P. O'BrienDirectorSep 2020
Theresa P. SextonDirectorSep 2020
Beth E. DozoretzDirectorDec 2018
John E. ChadwickDirectorDec 2018
Joseph E. AntonDirectorDec 2018
Ronald I. DozoretzDirectorDec 2018
Theresa E. SextonDirectorDec 2018
Michael I. KofflerDirectorOct 2018
Rina E. WolfDirectorOct 2018
Ronald I. DozoretzPromoterDec 2018
Michael I. KofflerPromoterOct 2017
Scott I. StorrerPromoterApr 2014